HCPLive 5 Stories in Under 5: Week of 03/16

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? Check out the HCPFive!

Top 5 Healthcare Headlines for March 16-23, 2025:

1. New ACP Guidelines Recommend Adding Triptan to NSAID or Acetaminophen for Migraines
The American College of Physicians now recommends adding a triptan to NSAIDs or acetaminophen for moderate to severe acute migraines and urges clinicians to initiate combination therapy early.

2. Automated Insulin Delivery Effectively Lowers HbA1c in Type 2 Diabetes
Tandem Diabetes Care’s Control-IQ+ automated insulin delivery system led to greater HbA1c reduction than continuous glucose monitoring alone in adults with insulin-requiring type 2 diabetes.

3. FDA Approves Guselkumab (Tremfya) For Crohn's Disease
The FDA approved guselkumab for moderately to severely active Crohn’s disease based on phase 3 trial data demonstrating superior efficacy over ustekinumab on endoscopic endpoints.

4. FDA Approves Oral Iptacopan (Fabhalta) as First C3 Glomerulopathy Therapy
The FDA approved iptacopan as the first therapy for C3 glomerulopathy, with phase 3 data showing significant proteinuria reduction and sustained efficacy at 12 months.

5. FDA Approves Vutrisiran (AMVUTTRA) for ATTR-CM
The FDA expanded vutrisiran’s approval for cardiomyopathy in transthyretin-mediated amyloidosis, making it the first RNAi therapeutic to reduce cardiovascular mortality and hospitalizations in ATTR-CM.